Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.78 |
| ▸ | KDM1A | O60341 | 2/20 | 0.76 |
| ▸ | EP300 | Q09472 | 4/20 | 0.66 |
| ▸ | BCHE | P06276 | 3/20 | 0.66 |
| ▸ | ACHE | P22303 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.66 |
| ▸ | DRD2 | P14416 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.66 |
| ▸ | RXRA | P19793 | 2/20 | 0.66 |
| ▸ | DRD1 | P21728 | 2/20 | 0.66 |
| ▸ | HTR2B | P41595 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | RAD52 | P43351 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31214707 | 1.00 | P2RX7 (0.78) | P2RX7KDM1AEP300BCHEACHE | |
| SCHEMBL13814556 | 0.91 | P2RX7 (0.81) | P2RX7KDM1AEP300BCHEACHE | |
| SCHEMBL14513599 | 0.88 | P2RX7 (0.62) | P2RX7KDM1AEP300BCHEACHE | |
| SCHEMBL13814501 | 0.88 | P2RX7 (0.76) | P2RX7KDM1AEP300BCHEACHE | |
| SCHEMBL298305 | 0.88 | P2RX7 (1.00) | P2RX7KDM1AEP300BCHEACHE | |
| Dehydrocorydaline SCHEMBL14513602 | 0.87 | KDM1A (1.00) | P2RX7KDM1AEP300ACHELMNA | |
| Dehydrocorydaline SCHEMBL29396913 | 0.87 | KDM1A (1.00) | P2RX7KDM1AEP300ACHELMNA | |
| SCHEMBL14513594 | 0.86 | P2RX7 (0.79) | P2RX7KDM1AEP300BCHEACHE | |
| SCHEMBL14513612 | 0.86 | P2RX7 (0.89) | P2RX7KDM1AEP300BCHEACHE | |
| Dehydrocorydaline SCHEMBL28839366 | 0.85 | KDM1A (0.98) | P2RX7KDM1AEP300ACHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9610281-B2 | Use and preparation method of berberine compounds | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2017-04-04 | — | — | US | disclosed |
| US-20150164870-A1 | USE AND PREPARATION METHOD OF BERBERINE COMPOUNDS | UNIVERSITY OF CALIFORNIA, IRVINE | 2015-06-18 | — | — | US | disclosed |
| EP-2427460-B1 | NOVEL ISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-26 | — | — | EP | disclosed |
| EP-2427460-B1 | NOVEL ISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8258149-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258149-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2427460-A1 | NOVEL ISOQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128061-A1 | NOVEL ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286396-A1 | NOVEL ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286396-A1 | NOVEL ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | disclosed |
| WO-2010128061-A1 | NOVEL ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| EP-2070926-A1 | 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2009-06-17 | — | — | EP | disclosed |
| US-20070098649-A1 | Method and composition for controlling oral pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (IL) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286396-A1 | NOVEL ISOQUINOLINE DERIVATIVES | CYP3A7, RAB7A, IPO7 | P2RX7 669/4885KDM1A 2024/4885EP300 1066/4885 |
| US-20070098649-A1 | Method and composition for controlling oral pathogens | BROX, NOP2, FBL | P2RX7 2447/4885KDM1A 3745/4885EP300 3990/4885 |
| US-20150164870-A1 | USE AND PREPARATION METHOD OF BERBERINE COMPOUNDS | OPRK1, OPRD1, OPRL1 | P2RX7 710/4885KDM1A 3496/4885EP300 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.